Integrated immunologic surveillance in heart transplantation: from alloimmune risk assessment to precision monitoring
Improved survival after heart transplantation has shifted the central clinical challenge from short-term graft loss to long-term threats posed by acute cellular rejection, antibody-mediated rejection, and cardiac allograft vasculopathy. Because rejection can progress silently before graft dysfunction becomes apparent, early and accurate immunologic risk assessment remains essential to preserving graft longevity. Advances in transplant immunology and molecular diagnostics have substantially expanded the tools available across the transplant continuum, ranging from high-resolution donor-specific antibody characterization to gene expression profiling and donor-derived cell-free DNA analysis for post-transplant surveillance. Rather than functioning as isolated tests, these modalities are increasingly interpreted together, providing a rationale for moving beyond routine biopsy-based monitoring, in selected recipients, toward adaptive, risk-stratified surveillance, although outcome evidence for such strategies remains limited. In this review, we summarize the biologic principles, clinical evidence, and limitations underlying these contemporary surveillance strategies, and outline how their integration, alongside emerging computational and epitope-level approaches, may reshape heart transplant care toward a more precise, individualized model of post-transplant monitoring.
Authors
- Daniella Galtes
- Mrudula Munagala
- Vidit Majmundar
Institutions
- University of Miami (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3389/fimmu.2026.1957605
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health